Market Research Report
Investigation Report on China's Botulinum Toxin Type A Market, 2020-2024
|Investigation Report on China's Botulinum Toxin Type A Market, 2020-2024|
Published: September 30, 2020
China Research and Intelligence
Content info: 40 Pages
Delivery time: 1-2 business days
On Apr. 15, 2002, Botulinum Toxin Type A was approved by the FDA as a medical cosmetic that is injected to temporarily improve the appearance of moderate to severe glabellar lines. Later, some generic drugs appeared on the market. In addition to the imported Botulinum Toxin Type A (trade name: Botox) produced by Allergan, the Botulinum Toxin Type A products in China also include Botulinum Toxin Type A (trade name: Hengli) developed by Lanzhou Institute of Biological Products Co., Ltd.
According to CRI's market research, Botulinum Toxin Type A has been growing rapidly since it entered China. From 2015 to 2019, its annual sales value increased from less than CNY104.88 million to CNY176.54 million, representing a CAGR of 13.9%.
In China, the medical use of Botulinum Toxin Type A is to treat adult blepharospasm and prosopospasm and some strabismuses, especially acute paralytic strabismus, concomitant strabismus, strabismus caused by endocrine diseases, and the strabismus that cannot be corrected surgically for those aged 12 and above. The incidence of facial neuropathy is increasing in China. Many people are attacked by prosopospasm when they are over-stressed or fatigued. Seeing global annual incidence of about 0.003%, facial neuropathy is more common in women than in men, and more common in middle-aged and elderly people than in people from other age groups.
However, more users of Botulinum Toxin Type A are women who pursue a thin face or less wrinkles. With more than 10 million cosmetic surgeries every year, the market size of medical beauty in China has exceeded USD 15 billion in 2019 and is still growing. As the demand for Botulinum Toxin Type A is expanding, some medical institutions and beauty salons have begun to inject Botulinum Toxin Type A smuggled from South Korea, France, Germany, etc. for their customers. Although the Chinese government only approved the sale of Botox and Hengli, smuggled Botulinum Toxin Type A products are easily available in China.
It is expected that, with the development of China's economy, the rise of income, and the change of consumption habit, Chinese people will spend more in medical beauty, and the market size of Botulinum Toxin Type A will continue to grow in China in 2020-2024.
Table of contents